HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy

BACKGROUND: Adjuvant therapy comprising the HER2 receptor antagonist trastuzumab is associated with a significant improvement in disease-free and overall survival as compared to chemotherapy alone in localized HER2-positive breast cancer (BC). However, a subset of HER2-positive tumors seems to respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Stocker, Albina, Hilbers, Marie-Luise, Gauthier, Claire, Grogg, Josias, Kullak-Ublick, Gerd A., Seifert, Burkhardt, Varga, Zsuzsanna, Trojan, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963084/
https://www.ncbi.nlm.nih.gov/pubmed/27463363
http://dx.doi.org/10.1371/journal.pone.0159176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963084/
https://www.ncbi.nlm.nih.gov/pubmed/27463363
http://dx.doi.org/10.1371/journal.pone.0159176

Ejemplares similares